# Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)

> **NCT06569602** · — · RECRUITING · sponsor: **Edwards Lifesciences** · enrollment: 500 (estimated)

## Conditions studied

- Tricuspid Valve Regurgitation
- Heart Valve Diseases
- Cardiovascular Diseases

## Interventions

- **DEVICE:** Transcatheter Tricuspid Valve Replacement

## Key facts

- **NCT ID:** NCT06569602
- **Lead sponsor:** Edwards Lifesciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2030-09-30
- **Final completion:** 2033-09-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569602, "Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06569602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*